Lisa Warsinger Martin, MD, FACC

General Statement of Disclosure:

EQUITY INTERESTS/STOCK OPTIONS: Abbott, Bristol-Meyers-Squibb, Crisper,Cytokinetics,Editas Medicine, Intuitive Surgical, Johnson &Johnson, Merck, Moderna, Proctor & Gamble, C4 Theraputics(NONE) RESEARCH/RESEARCH GRANTS: Anthera - Cleveland Clinic trial - study site- finished >12 months ago(MODEST), Novartis - Harvard Hospitals- Brigham, I think- finished > 12 months ago(MODEST), Amarin Reduce-IT trial - EPA Omega 3 randomized trial for triglycerides-finished > 12 months ago(MODEST), Pfizer finished >12 months ago(MODEST), ROCHE -Daletrapib trial finished >12 months ago(MODEST), Novartis ASTRONAUT multicenter trial finished >12 months ago 2013 Aliskiren(MODEST)

View Full Disclosure